1-[4-(2,5-dideuterio-3-dodecylpyrrolidin-1-yl)-2,2,6,6-tetramethylpiperidin-1-yl]ethanone
C27H52N2O — CID 151336850
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[4-(2,5-dideuterio-3-dodecylpyrrolidin-1-yl)-2,2,6,6-tetramethylpiperidin-1-yl]ethanone
1-[4-(2,5-dideuterio-3-dodecylpyrrolidin-1-yl)-2,2,6,6-tetramethylpiperidin-1-yl]ethanone (PubChem CID 151336850) has the molecular formula C27H52N2O and a molecular weight of 422.74 g/mol. Its IUPAC name is 1-[4-(2,5-dideuterio-3-dodecylpyrrolidin-1-yl)-2,2,6,6-tetramethylpiperidin-1-yl]ethanone.
Molecular Properties
| Compound Name | 1-[4-(2,5-dideuterio-3-dodecylpyrrolidin-1-yl)-2,2,6,6-tetramethylpiperidin-1-yl]ethanone |
|---|---|
| PubChem CID | 151336850 |
| Molecular Formula | C27H52N2O |
| Molecular Weight | 422.74 g/mol |
| Exact Mass | 422.42 |
| IUPAC Name | 1-[4-(2,5-dideuterio-3-dodecylpyrrolidin-1-yl)-2,2,6,6-tetramethylpiperidin-1-yl]ethanone |
| SMILES | [2H]C1CC(CCCCCCCCCCCC)C([2H])N1C1CC(C)(C)N(C(C)=O)C(C)(C)C1 |
| InChI | InChI=1S/C27H52N2O/c1-7-8-9-10-11-12-13-14-15-16-17-24-18-19-28(22-24)25-20-26(3,4)29(23(2)30)27(5,6)21-25/h24-25H,7-22H2,1-6H3/i19D,22D |
| InChIKey | OJPROWLBWIZGHD-IKQLPDBLSA-N |
| XLogP | 7.19 |
| TPSA | 23.55 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 2 |
| Rotatable Bonds | 12 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 422.74 |
| LogP ≤ 5 | 7.19 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 2 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 151336850 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.